NexImmune, Inc.

NexImmune, Inc. is a clinical-stage biotechnology company specializing in developing T cell immunotherapies for cancer and immune-mediated diseases. The company's proprietary Artificial Immune Modulation nanoparticle technology platform is the foundation for its product candidates, including NEXI-001, an allogeneic cell therapy for acute myeloid leukemia, NEXI-002, an autologous cell therapy for multiple myeloma, and NEXI-003, a candidate targeted against HPV-associated malignancies. These therapies are in various stages of clinical development, with the potential to address unmet medical needs and generate revenue through successful commercialization.